Re: Nonlocalized lower gastrointestinal bleeding: provocative bleeding studies with intraarterial tPA, heparin, and tolazoline.
Smith
Douglas C
DC
Watkins
Gregory E
GE
D000925:Anticoagulants / Q000009:adverse effects*; D004621:Embolization, Therapeutic; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000628:therapy; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D007261:Infusions, Intra-Arterial; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*; D014043:Tolazoline / Q000009:adverse effects*; D014667:Vasopressins / Q000627:therapeutic use
D000925:Anticoagulants; D014667:Vasopressins; D006493:Heparin; D014043:Tolazoline; D010959:Tissue Plasminogen Activator